BLUEBIRD BIO INC (BLUE) Fundamental Analysis & Valuation

NASDAQ:BLUE • US09609G2093

4.97 USD
0 (0%)
At close: May 30, 2025
4.99 USD
+0.02 (+0.4%)
After Hours: 5/30/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BLUE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BLUE. BLUE was compared to 520 industry peers in the Biotechnology industry. Both the profitability and financial health of BLUE have multiple concerns. BLUE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. BLUE Profitability Analysis

1.1 Basic Checks

  • BLUE had negative earnings in the past year.
  • BLUE had a negative operating cash flow in the past year.
  • BLUE had negative earnings in each of the past 5 years.
  • BLUE had a negative operating cash flow in each of the past 5 years.
BLUE Yearly Net Income VS EBIT VS OCF VS FCFBLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

  • The Return On Assets of BLUE (-67.57%) is worse than 63.15% of its industry peers.
Industry RankSector Rank
ROA -67.57%
ROE N/A
ROIC N/A
ROA(3y)-44.86%
ROA(5y)-61.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLUE Yearly ROA, ROE, ROICBLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • BLUE's Gross Margin of 27.12% is fine compared to the rest of the industry. BLUE outperforms 73.52% of its industry peers.
  • BLUE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLUE Yearly Profit, Operating, Gross MarginsBLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. BLUE Health Analysis

2.1 Basic Checks

  • BLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BLUE has more shares outstanding
  • BLUE has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BLUE is higher compared to a year ago.
BLUE Yearly Shares OutstandingBLUE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BLUE Yearly Total Debt VS Total AssetsBLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • BLUE has an Altman-Z score of -23.91. This is a bad value and indicates that BLUE is not financially healthy and even has some risk of bankruptcy.
  • BLUE has a Altman-Z score of -23.91. This is amonst the worse of the industry: BLUE underperforms 86.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.91
ROIC/WACCN/A
WACC6.98%
BLUE Yearly LT Debt VS Equity VS FCFBLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 0.55 indicates that BLUE may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.55, BLUE is doing worse than 91.95% of the companies in the same industry.
  • A Quick Ratio of 0.29 indicates that BLUE may have some problems paying its short term obligations.
  • The Quick ratio of BLUE (0.29) is worse than 93.92% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.29
BLUE Yearly Current Assets VS Current LiabilitesBLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BLUE Growth Analysis

3.1 Past

  • BLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.44%, which is quite impressive.
  • The Revenue has grown by 127.42% in the past year. This is a very strong growth!
  • The Revenue has been growing by 183.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.61%
Revenue 1Y (TTM)127.42%
Revenue growth 3Y183.97%
Revenue growth 5YN/A
Sales Q2Q%108.43%

3.2 Future

  • Based on estimates for the next years, BLUE will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.65% on average per year.
  • Based on estimates for the next years, BLUE will show a very strong growth in Revenue. The Revenue will grow by 41.63% on average per year.
EPS Next Y52.54%
EPS Next 2Y31.17%
EPS Next 3Y21.55%
EPS Next 5Y14.65%
Revenue Next Year199.26%
Revenue Next 2Y86.57%
Revenue Next 3Y52.44%
Revenue Next 5Y41.63%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BLUE Yearly Revenue VS EstimatesBLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLUE Yearly EPS VS EstimatesBLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

1

4. BLUE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BLUE. In the last year negative earnings were reported.
  • Also next year BLUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLUE Price Earnings VS Forward Price EarningsBLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLUE Per share dataBLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BLUE's earnings are expected to grow with 21.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.17%
EPS Next 3Y21.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLUE Dividend Analysis

5.1 Amount

  • BLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BLUE Fundamentals: All Metrics, Ratios and Statistics

BLUEBIRD BIO INC

NASDAQ:BLUE (5/30/2025, 8:00:01 PM)

After market: 4.99 +0.02 (+0.4%)

4.97

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14
Earnings (Next)08-12
Inst Owners39.69%
Inst Owner Change-99.74%
Ins Owners0.17%
Ins Owner Change0%
Market Cap48.66M
Revenue(TTM)103.95M
Net Income(TTM)-199.98M
Analysts76
Price Target8.84 (77.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)25.85%
Max EPS beat(2)51.6%
EPS beat(4)4
Avg EPS beat(4)23.8%
Min EPS beat(4)1.18%
Max EPS beat(4)51.6%
EPS beat(8)7
Avg EPS beat(8)13.99%
EPS beat(12)9
Avg EPS beat(12)16.85%
EPS beat(16)9
Avg EPS beat(16)9.44%
Revenue beat(2)2
Avg Revenue beat(2)20.18%
Min Revenue beat(2)0.87%
Max Revenue beat(2)39.48%
Revenue beat(4)2
Avg Revenue beat(4)-9.23%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)39.48%
Revenue beat(8)2
Avg Revenue beat(8)-18.74%
Revenue beat(12)3
Avg Revenue beat(12)-25.88%
Revenue beat(16)4
Avg Revenue beat(16)-26.4%
PT rev (1m)20.37%
PT rev (3m)-57.93%
EPS NQ rev (1m)-53.7%
EPS NQ rev (3m)-85.69%
EPS NY rev (1m)-2.52%
EPS NY rev (3m)-30.96%
Revenue NQ rev (1m)-27.13%
Revenue NQ rev (3m)-27.13%
Revenue NY rev (1m)-13.16%
Revenue NY rev (3m)-14.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.53
EYN/A
EPS(NY)-6.92
Fwd EYN/A
FCF(TTM)-23.54
FCFYN/A
OCF(TTM)-23.37
OCFYN/A
SpS10.62
BVpS-5.91
TBVpS-7.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.12%
FCFM N/A
ROA(3y)-44.86%
ROA(5y)-61.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.74%
Cap/Sales 1.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.29
Altman-Z -23.91
F-Score2
WACC6.98%
ROIC/WACCN/A
Cap/Depr(3y)100.07%
Cap/Depr(5y)113.4%
Cap/Sales(3y)133.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.61%
EPS Next Y52.54%
EPS Next 2Y31.17%
EPS Next 3Y21.55%
EPS Next 5Y14.65%
Revenue 1Y (TTM)127.42%
Revenue growth 3Y183.97%
Revenue growth 5YN/A
Sales Q2Q%108.43%
Revenue Next Year199.26%
Revenue Next 2Y86.57%
Revenue Next 3Y52.44%
Revenue Next 5Y41.63%
EBIT growth 1Y36.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.42%
EBIT Next 3Y25.28%
EBIT Next 5Y23.54%
FCF growth 1Y29.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.21%
OCF growth 3YN/A
OCF growth 5YN/A

BLUEBIRD BIO INC / BLUE FAQ

What is the fundamental rating for BLUE stock?

ChartMill assigns a fundamental rating of 2 / 10 to BLUE.


Can you provide the valuation status for BLUEBIRD BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to BLUEBIRD BIO INC (BLUE). This can be considered as Overvalued.


What is the profitability of BLUE stock?

BLUEBIRD BIO INC (BLUE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BLUE stock?

The Earnings per Share (EPS) of BLUEBIRD BIO INC (BLUE) is expected to grow by 52.54% in the next year.